|
WO2019195609A2
(en)
|
2018-04-04 |
2019-10-10 |
Arvinas Operations, Inc. |
Modulators of proteolysis and associated methods of use
|
|
UA129778C2
(uk)
|
2019-10-28 |
2025-07-30 |
Мерк Шарп Енд Доум Елелсі |
Низькомолекулярні інгібітори g12c-мутантного kras
|
|
EP4067343A4
(en)
|
2019-11-29 |
2024-01-03 |
Taiho Pharmaceutical Co., Ltd. |
NEW PHENOLIC COMPOUND OR SALT THEREOF
|
|
CR20240508A
(es)
|
2022-05-19 |
2024-12-20 |
Genentech Inc |
Compuestos aza-tetracíclicos de oxazepina y usos de los mismos
|
|
AU2023302139A1
(en)
*
|
2022-07-05 |
2024-12-19 |
Pfizer Inc. |
Pyrido[4,3-d]pyrimidine compounds
|
|
CN119790058A
(zh)
*
|
2022-07-09 |
2025-04-08 |
荣山医药股份有限公司 |
用于治疗疾病的稠合环kras抑制剂
|
|
IL318647A
(en)
|
2022-08-05 |
2025-03-01 |
Kumquat Biosciences Inc |
Heterocyclic compounds and their uses
|
|
JP2025528126A
(ja)
*
|
2022-08-11 |
2025-08-26 |
ベイジン スウィッツアランド ゲゼルシャフト ミット ベシュレンクテル ハフツング |
複素環式化合物、その組成物、及びそれらによる処置方法
|
|
WO2024032747A1
(zh)
*
|
2022-08-12 |
2024-02-15 |
正大天晴药业集团股份有限公司 |
三环类化合物及其医药用途
|
|
WO2024041573A1
(en)
*
|
2022-08-25 |
2024-02-29 |
Zai Lab (Shanghai) Co., Ltd. |
Fused multi-heterocyclic compounds as kras g12d modulators and uses thereof
|
|
TW202430179A
(zh)
|
2022-11-21 |
2024-08-01 |
美商樹線生物科學公司 |
螺環二氫哌喃并嘧啶ＫＲａｓ抑制劑
|
|
AU2023388747A1
(en)
*
|
2022-12-07 |
2025-07-10 |
Jacobio Pharmaceuticals Co., Ltd. |
Fused cyclic compounds and use thereof
|
|
US12448399B2
(en)
|
2023-01-26 |
2025-10-21 |
Arvinas Operations, Inc. |
Cereblon-based KRAS degrading PROTACs and uses related thereto
|
|
WO2024178304A1
(en)
*
|
2023-02-24 |
2024-08-29 |
Alterome Therapeutics, Inc. |
Kras modulators
|
|
AU2024241633A1
(en)
|
2023-03-30 |
2025-11-06 |
Revolution Medicines, Inc. |
Compositions for inducing ras gtp hydrolysis and uses thereof
|
|
PE20252775A1
(es)
*
|
2023-04-05 |
2025-12-22 |
Pfizer |
Compuestos de pirido[4,3-d]pirimidina
|
|
WO2024208305A1
(zh)
*
|
2023-04-07 |
2024-10-10 |
江苏恒瑞医药股份有限公司 |
稠合四环类化合物、其制备方法及其在医药上的应用
|
|
EP4695262A1
(en)
*
|
2023-04-10 |
2026-02-18 |
Pfizer Inc. |
Pyrido[4,3-d]pyrimidine compounds
|
|
AU2024252725A1
(en)
*
|
2023-04-11 |
2025-11-06 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
WO2024218686A1
(en)
*
|
2023-04-20 |
2024-10-24 |
Pfizer Inc. |
Pyrido[4,3-d]pyrimidine compounds
|
|
TW202508595A
(zh)
|
2023-05-04 |
2025-03-01 |
美商銳新醫藥公司 |
用於ｒａｓ相關疾病或病症之組合療法
|
|
CN121194980A
(zh)
*
|
2023-05-16 |
2025-12-23 |
和记黄埔医药（上海）有限公司 |
三环类化合物及其用途
|
|
EP4735438A2
(en)
*
|
2023-06-30 |
2026-05-06 |
Merck Patent GmbH |
Heterobifunctional compounds for the degradation of kras
|
|
US20250049810A1
(en)
|
2023-08-07 |
2025-02-13 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
WO2025038936A1
(en)
|
2023-08-17 |
2025-02-20 |
Treeline Biosciences, Inc. |
Spirocyclic dihydropyranopyrimidine kras inhibitors
|
|
WO2025049619A1
(en)
|
2023-08-29 |
2025-03-06 |
Quanta Therapeutics, Inc. |
Kras modulators and uses thereof
|
|
US20250109147A1
(en)
|
2023-09-08 |
2025-04-03 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
TW202528315A
(zh)
|
2023-09-21 |
2025-07-16 |
美商樹線生物科學公司 |
螺環二氫哌喃并吡啶ＫＲａｓ抑制劑
|
|
AU2024360465A1
(en)
|
2023-10-12 |
2026-04-09 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
|
AU2024361909A1
(en)
|
2023-10-20 |
2026-03-26 |
Merck Sharp & Dohme Llc |
Small molecule inhibitors of kras proteins
|
|
CN117700374A
(zh)
*
|
2023-12-25 |
2024-03-15 |
吉尔多肽生物制药(大连市)有限公司 |
手性高吗啉-3-甲酸的制备方法
|
|
WO2025148868A1
(zh)
*
|
2024-01-08 |
2025-07-17 |
泰励生物科技（上海）有限公司 |
一种抗体偶联药物及其用途
|
|
WO2025168072A1
(en)
*
|
2024-02-08 |
2025-08-14 |
Beigene (Suzhou) Co., Ltd. |
Heterocyclic compounds, compositions thereof, and methods of treatment therewith
|
|
WO2025171296A1
(en)
|
2024-02-09 |
2025-08-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
TW202547461A
(zh)
|
2024-05-17 |
2025-12-16 |
美商銳新醫藥公司 |
Ｒａｓ抑制劑
|
|
WO2025245127A1
(en)
|
2024-05-21 |
2025-11-27 |
Treeline Biosciences, Inc. |
Spirocyclic dihydropyranopyrimidine kras inhibitors
|
|
WO2025255438A1
(en)
|
2024-06-07 |
2025-12-11 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
WO2025265060A1
(en)
|
2024-06-21 |
2025-12-26 |
Revolution Medicines, Inc. |
Therapeutic compositions and methods for managing treatment-related effects
|
|
WO2026006747A1
(en)
|
2024-06-28 |
2026-01-02 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026015825A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Use of ras inhibitor for treating pancreatic cancer
|
|
WO2026015790A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015796A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015801A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026035945A1
(en)
|
2024-08-07 |
2026-02-12 |
Tesseract Medicines Us, Llc |
Covalent-induced drug conjugates targeting kras and comprising a topoisomerase payload
|
|
WO2026035947A1
(en)
|
2024-08-07 |
2026-02-12 |
Tesseract Medicines Us, Llc |
Kras-targeting covalent-induced drug conjugates comprising a topoisomerase payload
|
|
WO2026050446A1
(en)
|
2024-08-29 |
2026-03-05 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026064527A1
(en)
|
2024-09-19 |
2026-03-26 |
Tesseract Medicines Us, Llc |
Kras-targeting covalent-induced drug conjugates comprising a tubulin inhibitor payload
|
|
WO2026064520A1
(en)
|
2024-09-19 |
2026-03-26 |
Tesseract Medicines Us, Llc |
Covalent-induced drug conjugates targeting kras and comprising a tubulin inhibitor payload
|
|
WO2026072904A2
(en)
|
2024-09-26 |
2026-04-02 |
Revolution Medicines, Inc. |
Compositions and methods for treating lung cancer
|